Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain

Observational and Cross-sectional Study to Assess the Sociodemographic and Clinical Characteristics of Patients Treated With RIVAROXABAN in the Context of Routine Clinical Practice of Spanish Haematologists, Cardiologists and Internists (HEROIC Study)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02262676

Acronym

HEROIC

Enrollment

2251

Registered

2014-10-13

Start date

2014-10-31

Completion date

2015-05-31

Last updated

2017-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Stroke prevention on Atrial Fibrillation, Prevention and Control, Stroke

Brief summary

Depict demographic and clinical features of patients with atrial fibrillation treated with rivaroxaban to prevent stroke and pulmonary embolism in routine clinical practice

Interventions

DRUGRivaroxaban (Xarelto, BAY59-7939)

Patients treated by Physicians under approved local prescriptions

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients ≥ 18 years * Patients with atrial fibrillation * Patients in treatment with rivaroxaban for stroke prevention in atrial fibrillation at least 3 months previous to inclusion period in study

Exclusion criteria

* Patients in treatment after start of study * Patients treated with other anticoagulant treatment

Design outcomes

Primary

Measure	Time frame
Demographic Data	At recruitment visit
Medical History	At recruitment visit

Secondary

Measure	Time frame	Description
Assess regional differences among the different Spanish autonomous communities on the management of patients with rivaroxaban treatment during the routine clinical practice	At recruitment visit	By use of Informe de Posicionamiento Terapéutico (Spanish Questionnaire)
Adherence to rivaroxaban treatment	At recruitment visit	By use of Morisky-Green questionnaire
Assess the satisfaction of rivaroxaban treatment	At recruitment visit	By use of Anti-Clot Treatment Scale (ACTS) questionnaire
Assess the quality of life in patients	At recruitment visit	By use of Short-Form 12 Health Survey,version 2 (SF12v2) questionnaire

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026